Heron Therapeutics, Inc. (HRTX:NASDAQ) closed at $0.280 on November 5, 2026, down 6.23% on the day. The stock trades 82.3% below its 52-week high of $1.58 and 7.7% above its 52-week low of $0.260. Over the past year, it lost 74.5%. Heron Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 5, 2025, HRTX closed higher on 96 days (38%). Its best day was April 24, 2026 (+19.00%) and its worst was June 2, 2026 (-45.78%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 1 time.
Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company's lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Find more stocks like HRTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.